News | November 12, 2021
Covaxin well tolerated with no safety concerns: Lancet
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Evidence also shows better immune response to virus among users of spray
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
The Lucent 3D Lumbar Interbody System features a functionally unique multi-component device manufactured in a 3D printing sequence
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
Trivector Biomed has been promoting its Novaerus air disinfection solution across hospitals and health care facilities across India.
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
The process is completed with the help of a balloon at a low temperature so that other cells are undamaged and the patient can return home the next day
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
Consolidation of the Acros Organics, Alfa Aesar and Maybridge brands to one single brand, Thermo Scientific
Subscribe To Our Newsletter & Stay Updated
